| Description |
1 online resource |
| Contents |
Part 1. Overview -- Historical Perspectives and Current Trends in Cancer Immunotherapy / Tyler J. Curiel -- T Cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment / Cailin Moira Wilke, Shuang Wei, Lin Wang, Ilona Kryczek and Jingyuan Fang, et al |
|
Part 2. Passive strategies to boost anti-tumor immunity -- Adoptive T Cell Transfer / Donald R. Shaffer, Conrad Russell Y. Cruz and Cliona M. Rooney -- Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts / K.F. Bol, G. Schreibelt, E.H.J.G. Aarntzen, I.J.M. de Vries and C.G. Figdor |
|
Part 3. Active strategies to boost anti-tumor immunity -- Peptide and Protein-Based Cancer Vaccines / Marion Braun, Rachel Perret, Godehard Scholz and Pedro Romero -- Antigen Targeting to Dendritic Cells for Cancer Immunotherapy / Dinja Oosterhoff, David T. Curiel and Tanja D. de Gruijl -- Cytokines in the Treatment of Cancer / Kim Margolin, Mark Lazarus and Howard L. Kaufman -- Immune Co-signaling to Treat Cancer / Margaret K. Callahan, Jedd D. Wolchok, James P. Allison and Padmanee Sharma -- Managing Regulatory T Cells to Improve Cancer Immunotherapy / Tyler J. Curiel -- Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and Therapeutic Perspectives / Paulo C. Rodríguez and Augusto C. Ochoa -- Antibodies as Cancer Immunotherapy / Devalingam Mahalingam and Tyler J. Curiel -- Targeted Toxins in Cancer Immunotherapy / Devalingam Mahalingam, Michael J. Brumlik, Reinhard Waehler, David T. Curiel and Tyler J. Curiel |
|
Part 4. Additional strategies and considerations -- Miscellaneous Approaches and Considerations: TLR Agonists and Other Inflammatory Agents, Anti-Chemokine Agents, Infectious Agents, Tumor Stroma Targeting, Age and Sex Effects, and Miscellaneous Small Molecules / Robert S. Svatek and Tyler J. Curiel -- Monitoring Antigen-Specific Responses in Clinical Trials of Cancer Immunotherapy / Audi G. Chapuis and Cassian Yee -- Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies / Marijo Bilusic, Ravi A. Madan and James L. Gulley |
| Summary |
This volume is a comprehensive discussion of the major factors affecting tumor immunology and a discussion of all major anti-cancer immunotherapeutic agents approved by the Food and Drug Administration of the United States and by European agencies. Many promising but unapproved agents in clinical trials are also discussed, as are key pre-clinical developments. The major challenges and intellectual issues facing investigators developing novel immunotherapeutics are discussed in detail as are conceptual developments influencing current and future treatment strategies. Each chapter begins by defining all relevant key terms and concepts and provides pertinent background information so that the text will be accessible to newcomers to the field as well as to the expert. This text book should provide an excellent reference resource for investigators in tumor immunology, life sciences students, drug developers designing novel anti-cancer immunotherapeutics, and to other individuals with some scientific training wishing to gain a better understanding of the field of tumor immunotherapy. Although the field is evolving rapidly, we have taken pains to ensure that information was as up to date as possible as the text went to press |
| Analysis |
Medicine |
|
Oncology |
|
Biomedicine |
|
Cancer Research |
|
Pharmacology/Toxicology |
| Bibliography |
Includes bibliographical references and index |
| Notes |
English |
| Subject |
Cancer -- Immunotherapy.
|
|
Immunotherapy.
|
|
Immunotherapy
|
|
Neoplasms -- immunology
|
|
Neoplasms -- therapy
|
|
HEALTH & FITNESS -- Diseases -- Cancer.
|
|
MEDICAL -- Oncology.
|
|
Immunotherapy
|
|
Cancer -- Immunotherapy
|
| Form |
Electronic book
|
| Author |
Curiel, Tyler J
|
| LC no. |
2012950052 |
| ISBN |
9781461447320 |
|
1461447321 |
|
1461447313 |
|
9781461447313 |
|
